Patent ID: 6982332

Claim:
A compound exhibiting CNS activity in mammalian species, having the structure wherein A is an optionally heterocyclic 5 or 6 membered aromatic ring system; is an optionally heteroevelic 5 or 6 membered aromatic ring structure wherein X and Y are moieties which complete said 5 or 6 membered aromatic ring system. R 2 is selected from the group consisting of C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 4-8 cycloalkyl, C 4-8 cycloalkenyl; C 6-10 aryl, —NR 4 q where R 4 individually are H, C 1-8 alkyl, C 2-8 alkenyl, C 4-8 cycloalkyl, C 4-8 cycloalkenyl, C 6-20 aryl and q is 3 or 4, with the proviso that when q is 4, the group bears a positive formal charge; —NR 4 —C(O)—R 4 , —NR 4 —C(O)—NR 4 2 wherein the above hydrocarbon groups may optional be substituted with —CN, C 1-4 lower alkyl, —OR 4 , and halo, or two R 2 together may form a fused ring system, o is an integer from 0 to 4, the upper limit of o bounded by the number of available substitutent sites on said optionally heterocyclic 5 or 6 membere aromatic ring structure; n is an integer from 0 to 2; R 1 is selected from the group consisting of C 18 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C 4-8 cycloalkyl, C 4-8 cycloalkenyl, C 6-10 aryl, each of the foregoing alkyl, a kenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl groups optionally halo substituted and/or substituted by —CN, C 1-4 lower alkoxy, C 1-4 acyloxy, C 1-4 acyl, or —C(O)—R 4 ;— —NH—SO 2 —NR 4 where R 5 is C 1-8 alkylene and r is 2 or 3, with the proviso that when r is 3, the nitrogen of the NR 4 r group will bear a positive formal charge; —R 5 —NH—C(O)—R 4 ; —R 5 —NR 4 r , —R 5 —Ar where Ar is an aryl ring system, optionally including one or more heteroatoms; and p is 1 to 4; wherein one (CH 2 ) n group may be replaced by O or S; or a pharmaceutically acceptable salt thereof.